Ahzantive (Aflibercept-Mrbb) for AMD

Overview
Ahzantive is approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD). It’s also indicated for macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ahzantive is also known by its drug name, aflibercept-mrbb.

Ahzantive is a biologic drug categorized as an anti-vascular endothelial growth factor (VEGF) therapy. It works by blocking VEGF, a protein that promotes the growth of abnormal blood vessels in the eye, thereby reducing leakage and swelling that can lead to vision loss in people with wet AMD.

How do I take it?
Prescribing information states that Ahzantive should be administered via intravitreal injection (injection into the eye). For wet AMD, dosing typically begins with injections every four weeks for the first three months. After this initial period, the dosing schedule typically changes to once every eight weeks. Dosing and scheduling can vary from person to person, as recommended by a health care provider. 

Side effects
Common side effects of Ahzantive include conjunctival hemorrhage (bleeding in the eye), eye pain, cataract formation, vitreous detachment (separation of the gel inside the eye), vitreous floaters (small moving spots in the field of vision), and increased intraocular pressure (pressure inside the eye).

Rare but serious side effects may include endophthalmitis (severe eye infection), retinal detachment (separation of the retina from the back of the eye), retinal vasculitis (inflammation of blood vessels in the retina), and arterial thromboembolic events (blood clots in arteries). 

For more information about this treatment, visit:

Ahzantive (Aflibercept-Mrbb) Injection, for Intravitreal Use — U.S. Food and Drug Administration 

Ahzantive FDA Approval History — Drugs.com